BenzingaAugust 6, 2026 at 3:31 AM NY29 days ago

Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story